Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Merck KGaA and Quintiles Announce Innovative Clinical Development Partnership

Published: Friday, May 17, 2013
Last Updated: Friday, May 17, 2013
Bookmark and Share
Agreement creates unique strategic collaboration for development and clinical trial execution.

Merck KGaA of Darmstadt, Germany, and Quintiles have announced a new, five-year clinical development agreement. This strategic collaboration is the first-of-its-kind between a biopharmaceutical company or division and a biopharmaceutical services provider, creating a comprehensive process that integrates the expertise and experience from both organizations into a single, well aligned clinical development engine.

In a novel approach to clinical development that is founded on a shared commitment to cost-disciplined science, the collaboration is intended to optimize productivity in the design and execution of studies with a focus on quality, speed and efficiency.

Under this agreement, Merck KGaA will shape and lead the strategy of its clinical development programs, with Quintiles directing clinical trial planning and execution.

Quintiles also will be a key contributor to Merck KGaA’s future clinical trial design activities. In this capacity, Quintiles will focus on delivering superior performance based on optimized clinical trial design and execution strategies, using highly efficient processes and proven technologies.

To fully leverage the expertise of both organizations, leaders from Quintiles will collaborate in strategic decision-making processes affecting the development of the portfolio of Merck KGaA’s prescription medicines division.

“By combining the strengths of Merck KGaA and Quintiles, we are creating a new model in clinical development that will unlock the knowledge and insights of both companies,” says Annalisa Jenkins, Executive Vice President and Head of Global Development and Medical at the division.

Jenkins continued, “This is an innovative and unique collaboration that will help to translate the highest-quality science into efficiency and agility throughout our clinical trials, while enhancing our competitive position in an increasingly challenging environment of clinical drug development.”

Moving forward, Quintiles will be the sole-primary provider of Merck KGaA’s outsourced clinical development services for its global clinical programs.

The agreement will span the full spectrum of clinical development, from Phase I through to post-marketing approvals.

Importantly, it will also allow the Merck KGaA division to expand its reach globally by leveraging the broad local expertise of Quintiles to implement development programs around the world.

“This agreement is built upon a long-standing commitment to trust and transparency between our two organizations, and I’m confident it will only be enhanced by this innovative relationship,” says Tom Pike, Chief Executive Officer at Quintiles.

Pike continued, “We are excited about the opportunities this collaboration provides as we work with Merck KGaA in a new and innovative manner that leverages the best of our combined capabilities. We view this as a key step forward not only for our two companies, but for the way the industry approaches the development of new therapies for the patients we ultimately serve.”

The agreement reflects a shared commitment between both organizations to delivering optimal performance in clinical development.

The objective is to expedite the delivery of new therapeutic options to patients with high medical need across the Merck KGaA division’s core research areas of neurology, oncology, immuno-oncology and immunology.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Merck Serono and Intrexon Announce Agreement
Collaboration and license agreement will focus on developing a next generation CAR-T platform to generate several drug candidates.
Thursday, April 02, 2015
Merck Serono Appoints Luciano Rossetti
Appointment of Rossetti as Executive Vice President and Global Head of Research & Development.
Thursday, July 17, 2014
Scientific News
NIH Begins Yellow Fever Vaccine Trial
NIH has initiated an early-stage clinical trial of a vaccine to protect against yellow fever.
Viable HIV Vaccine Confirmed by Study
HIV Study in macaques confirms clinically viable vaccine opening the way for future treatment in humans.
PREVAIL Treatment Trial for Men with Persistent Ebola Viral RNA
The six-month study will enroll 60 to 120 EVD survivors.
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
Investigational Malaria Vaccine Protects Healthy U.S. Adults
Researchers at NIH have found that the malaria vaccine protected a small number of healthy, malaria-naïve adults in the U.S. from infection for more than one year after immunization.
AACR 2016: Cancer Immunotherapy and Beyond
At this year's meeting there was a palpable buzz around subjects ranging from microbiomics to the tumor microenvironment and cancer vaccines, big data to in vitro and in vivo modeling and drug delivery (to name just a few).
New Database for Sharing MS Clinical Trial Data
A new database containing nearly 2500 patient records from the placebo arms of nine multiple sclerosis (MS) clinical trials is now available for research by qualified investigators.
Study Finds Factors That May Influence Influenza Vaccine Effectiveness
Researchers at NIH have suggested that the long-held approach to predicting seasonal influenza vaccine effectiveness may need to be revisited.
BMS’s Opdivo Clinical Trial Shows Promise
Safety profile of the combination regimen from CheckMate -069 was consistent with previously reported studies and adverse events were managed using established safety algorithms.
Treatment of Common Prostate Cancer
Researchers at UTSW have found that the prostate cancer treatments suppress immune response and may promote relapse.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!